Inclusion of Women in Clinical Trials: Policies for Population Subgroups

Board on Health Sciences Policy

Division of Health Sciences Policy

INSTITUTE OF MEDICINE

NATIONAL ACADEMY PRESS
Washington, D.C. 1993



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page R1
Inclusion of Women in Clinical Trials: Policies for Population Subgroups Inclusion of Women in Clinical Trials: Policies for Population Subgroups Board on Health Sciences Policy Division of Health Sciences Policy INSTITUTE OF MEDICINE NATIONAL ACADEMY PRESS Washington, D.C. 1993

OCR for page R1
Inclusion of Women in Clinical Trials: Policies for Population Subgroups NATIONAL ACADEMY PRESS 2101 Constitution Avenue, N.W., Washington, D.C. 20418 NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are draw from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. This report has been reviewed by a group other than the authors according to procedures approved by a Report Review Committee consisting of member of the National Academy of Sciences, the National Academy of Engineeing, and the Institute of Medicine. The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate profession in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Science by its congressional charter to be an adviser to the federal government and, upon its own initiative to identify issues of medical care, research, and education Dr. Kenneth I.Shine is president of the Institute of Medicine. Support of this activity was provided by the Howard Hughes Medical Institute. The opinions and conclusions expressed here are those of the author and do not necessarily represent the views of the Howard Hughes Medical Institute, the National Academy of Sciences, or any of their constituent parts. Additional copies of this report are available in limited quantities from the Board on Health Sciences Policy, 2101 Constitution Avenue, N.W., Washington, DC 20418. Copyright 1993 by the National Academy of Sciences. All rights reserved. Printed in the United States of America The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The image adopted as a logotype by the Institute of Medicine is based on a relief carving from ancient Greece, now held by the Staatlichemuseen in Berlin.

OCR for page R1
Inclusion of Women in Clinical Trials: Policies for Population Subgroups BOARD ON HEALTH SCIENCES POLICY* J.CLAUDE BENNETT, Chair, Professor and Chairman, Department of Medicine, The University of Alabama School of Medicine, Birmingham EMILIO DADDARIO, Washington D.C. WILLIAM N.HUBBARD, Jr., President (retired), The Upjohn Company, Hickory Corners, Michigan THOMAS INUI, Professor and Chairman, Department of Ambulatory Care and Prevention, Harvard Medical School, Harvard Community Health Plan RICHARD J.JOHNS, Distinguished Service Professor, Department of Biomedical Engineering, The Johns Hopkins University School of Medicine ERIC R.KANDEL, University Professor and Senior Investigator, Center for Neurobiology and Behavior, Columbia College of Physicians and Surgeons PATRICIA KING, Professor of Law, Georgetown University Law Center SHELDON S.KING, President and CEO, Cedars-Sinai Medical Center, Los Angeles, California ELAINE L.LARSON, Dean, School of Nursing, Georgetown University JOSHUA LEDERBERG, Ph.D., University Professor, The Rockefeller University ROBERT I.LEVY, President, Wyeth-Ayerst Research, Philadelphia MARY LAKE POLAN, Chairperson, Department of Obstetrics and Gynecology Stanford University JOHN D.STOBO, Director, Department of Medicine and Physician-in-Chief, The Johns Hopkins Hospital, Baltimore, Maryland PAUL D.STOLLEY, Professor and Chairman, Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore JOHN E.WENNBERG, Director, The Center for the Evaluative Clinical Sciences, Dartmouth Medical School JEAN DONALD WILSON, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas Staff Jessica Townsend, Study Director Janet Wittes, Consultant Ruth Ellen Bulger, Director Philomina Mammen, Administrative Assistant *   At the time this report was written.

OCR for page R1
Inclusion of Women in Clinical Trials: Policies for Population Subgroups This page in the original is blank.